Efficacy and safety of trabectedin and pegylated liposomal doxorubicin in elderly patients: a subgroup analysis of a retrospective cohort.

Elderly patients with recurrent ovarian cancer are often underrepresented in clinical trials, complicating treatment decisions because of comorbidities and altered drug tolerance. Trabectedin plus pegylated liposomal doxorubicin is a non-platinum opt…

Preview only. Read the full abstract at the source